Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction. In parallel, Cyclerion is advancing CY6463, a central nervous system-penetrant sGC stimulator, in neurocognitive and neurodegenerative disorders. Both programs are supported by preclinical and early-stage clinical data suggesting potential benefits in modulating cGMP signaling across multiple organ systems. Cyclerion leverages a modular research platform to optimize pharmacokinetic and pharmacodynamic properties for both systemic and brain-targeted therapies.

Founded in May 2018 as a spin-out from Ironwood Pharmaceuticals, Cyclerion is headquartered in Cambridge, Massachusetts, with research collaborations and clinical sites spanning the United States and Europe. The company is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. Cyclerion continues to build on its translational science capabilities to expand its pipeline of sGC-based therapeutics and explore strategic partnerships to advance its programs toward regulatory milestones.

Key Stats

• Today's Range: $3.07 to $3.16
• 50-Day Range: $1.30 to $6.38
• 52-Week Range: $1.03 to $8.48
• Volume: 48,245 shs
• Average Volume: 4.31 million shs
• Market Capitalization: $13.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Cyclerion Therapeutics Stock Analysis - MarketRank™

Cyclerion Therapeutics scored higher than 2% of companies evaluated by MarketBeat, and ranked 854th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Cyclerion Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cyclerion Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cyclerion Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclerion Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclerion Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclerion Therapeutics has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CYCN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclerion Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclerion Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cyclerion Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CYCN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCN
• CIK: 1755237
• Web: www.cyclerion.com
• Phone: (857) 327-8778
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.53 million
• Net Margins: -170.11%
• Pretax Margin: -170.11%
• Return on Equity: -39.23%
• Return on Assets: -35.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.15
• Quick Ratio: 5.15

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 6.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.31 per share
• Price / Book: 1.34

Miscellaneous

• Outstanding Shares: 4,330,000
• Free Float: 2,845,000
• Market Cap: $13.42 million
• Optionable: No Data
• Beta: 1.80